All of these have several characteristics in common, such as age at presentation (older than 50–60 y.o.), aggressive clinical course, frequent sarcomatoid or mesenchymal-like appearance in cytokeratin+ cells, coexistence of residual well-differentiated carcinoma areas, and TP53 gene mutation (black or null immunohistochemistry patterns for p53), in a sea of other non-common genetic alterations. The gene discussed is TP53; the disease is carcinoma.